Durect corporation announces dur-928 phase 2a alcoholic hepatitis study results selected for late-breaking oral presentation at the liver meeting® 2019

Durect corporation announced that the results from the recently completed phase 2a study of dur-928 in patients with alcoholic hepatitis (ah) have been selected for an oral presentation as part of the late-breaking session of the liver meeting® 2019, the annual meeting of the american association for the study of liver diseases (aasld), taking place on november 8-12, 2019, in boston. this late-breaking abstract was one of only 29 late-breaking abstracts selected out of a total of approximately 3,000 abstracts that were accepted for presentation at the meeting. additionally, the study results were selected for inclusion in the 'best of the liver meeting' summary slide presentation in the alcohol-related liver disease category. tarek hassanein, m.d., one of the trial's principal investigators, will deliver the oral presentation of the detailed trial results. in a separate poster presentation, craig mcclain, m.d., will present additional comparative data from the phase 2a clinical trial of dur-928 and a control group from a contemporaneous ah trial conducted at university of louisville.
DRRX Ratings Summary
DRRX Quant Ranking